Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women

Enrico M. Messalli, Giampaolo Mainini, Cono Scaffa, Angela Cafiero, Pier Luigi Salzillo, Angelo Ragucci, Luigi Cobellis

Research output: Contribution to journalArticle

Abstract

Objectives: Osteoprotegerin (OPG) is a protein expressed by osteoblasts that, linking the receptor activator of nuclear factor κB (RANK) ligand (RANKL), produced by osteoblasts, blocks the process of osteoclastic differentiation and modulates osteoclastic apoptosis. Raloxifene (RAL) stimulates the production of OPG from osteoblasts, as demonstrated in vitro, carring out their antiresorption activity, at least in part, as means of the OPG/RANK/RANKL system. The aim of this study was to evaluate in vivo if the RAL treatment of postmenopausal women was associated to changes in serum OPG; moreover, to evaluate the serum changes of bone turnover modulators interleukin-6 (IL-6) and C-telopeptides of type-1 collagen (CrossLaps). Methods: A prospective, randomized, placebo-controlled study was designed. A group of consecutive healthy postmenopausal women (n = 40) referred to II Menopause Centre of the Department of Gynaecology of Second University of Naples for climacteric syndrome was enrolled and divided in two groups: (n = 20) postmenopausal women received for 6 months oral raloxifene (60 mg/day) versus (n = 20) postmenopausal women received placebo tablets. Results: Serum OPG levels in postmenopausal women after RAL treatment are statistically significant increased (P <0.001) versus baseline (P = 0.007) versus placebo. Conclusions: These in vivo data demonstrate that RAL could improve osteoporosis, also through an increase of OPG production by osteoblasts.

Original languageEnglish
Pages (from-to)38-44
Number of pages7
JournalMaturitas
Volume56
Issue number1
DOIs
Publication statusPublished - Jan 20 2007

Fingerprint

Osteoprotegerin
Osteoblasts
Serum
RANK Ligand
glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine
Placebos
Therapeutics
Gynecology
Bone Remodeling
Cytoplasmic and Nuclear Receptors
Menopause
Collagen Type I
Modulators
Tablets
Osteoporosis
Raloxifene Hydrochloride
Interleukin-6
Bone
Apoptosis
Proteins

Keywords

  • Menopause
  • Osteoporosis
  • Osteoprotegerin
  • Raloxifene

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology

Cite this

Messalli, E. M., Mainini, G., Scaffa, C., Cafiero, A., Salzillo, P. L., Ragucci, A., & Cobellis, L. (2007). Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 56(1), 38-44. https://doi.org/10.1016/j.maturitas.2006.05.007

Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. / Messalli, Enrico M.; Mainini, Giampaolo; Scaffa, Cono; Cafiero, Angela; Salzillo, Pier Luigi; Ragucci, Angelo; Cobellis, Luigi.

In: Maturitas, Vol. 56, No. 1, 20.01.2007, p. 38-44.

Research output: Contribution to journalArticle

Messalli, EM, Mainini, G, Scaffa, C, Cafiero, A, Salzillo, PL, Ragucci, A & Cobellis, L 2007, 'Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women', Maturitas, vol. 56, no. 1, pp. 38-44. https://doi.org/10.1016/j.maturitas.2006.05.007
Messalli, Enrico M. ; Mainini, Giampaolo ; Scaffa, Cono ; Cafiero, Angela ; Salzillo, Pier Luigi ; Ragucci, Angelo ; Cobellis, Luigi. / Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. In: Maturitas. 2007 ; Vol. 56, No. 1. pp. 38-44.
@article{92f1fc0a5e384c04b9ad10849cdcd712,
title = "Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women",
abstract = "Objectives: Osteoprotegerin (OPG) is a protein expressed by osteoblasts that, linking the receptor activator of nuclear factor κB (RANK) ligand (RANKL), produced by osteoblasts, blocks the process of osteoclastic differentiation and modulates osteoclastic apoptosis. Raloxifene (RAL) stimulates the production of OPG from osteoblasts, as demonstrated in vitro, carring out their antiresorption activity, at least in part, as means of the OPG/RANK/RANKL system. The aim of this study was to evaluate in vivo if the RAL treatment of postmenopausal women was associated to changes in serum OPG; moreover, to evaluate the serum changes of bone turnover modulators interleukin-6 (IL-6) and C-telopeptides of type-1 collagen (CrossLaps). Methods: A prospective, randomized, placebo-controlled study was designed. A group of consecutive healthy postmenopausal women (n = 40) referred to II Menopause Centre of the Department of Gynaecology of Second University of Naples for climacteric syndrome was enrolled and divided in two groups: (n = 20) postmenopausal women received for 6 months oral raloxifene (60 mg/day) versus (n = 20) postmenopausal women received placebo tablets. Results: Serum OPG levels in postmenopausal women after RAL treatment are statistically significant increased (P <0.001) versus baseline (P = 0.007) versus placebo. Conclusions: These in vivo data demonstrate that RAL could improve osteoporosis, also through an increase of OPG production by osteoblasts.",
keywords = "Menopause, Osteoporosis, Osteoprotegerin, Raloxifene",
author = "Messalli, {Enrico M.} and Giampaolo Mainini and Cono Scaffa and Angela Cafiero and Salzillo, {Pier Luigi} and Angelo Ragucci and Luigi Cobellis",
year = "2007",
month = "1",
day = "20",
doi = "10.1016/j.maturitas.2006.05.007",
language = "English",
volume = "56",
pages = "38--44",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women

AU - Messalli, Enrico M.

AU - Mainini, Giampaolo

AU - Scaffa, Cono

AU - Cafiero, Angela

AU - Salzillo, Pier Luigi

AU - Ragucci, Angelo

AU - Cobellis, Luigi

PY - 2007/1/20

Y1 - 2007/1/20

N2 - Objectives: Osteoprotegerin (OPG) is a protein expressed by osteoblasts that, linking the receptor activator of nuclear factor κB (RANK) ligand (RANKL), produced by osteoblasts, blocks the process of osteoclastic differentiation and modulates osteoclastic apoptosis. Raloxifene (RAL) stimulates the production of OPG from osteoblasts, as demonstrated in vitro, carring out their antiresorption activity, at least in part, as means of the OPG/RANK/RANKL system. The aim of this study was to evaluate in vivo if the RAL treatment of postmenopausal women was associated to changes in serum OPG; moreover, to evaluate the serum changes of bone turnover modulators interleukin-6 (IL-6) and C-telopeptides of type-1 collagen (CrossLaps). Methods: A prospective, randomized, placebo-controlled study was designed. A group of consecutive healthy postmenopausal women (n = 40) referred to II Menopause Centre of the Department of Gynaecology of Second University of Naples for climacteric syndrome was enrolled and divided in two groups: (n = 20) postmenopausal women received for 6 months oral raloxifene (60 mg/day) versus (n = 20) postmenopausal women received placebo tablets. Results: Serum OPG levels in postmenopausal women after RAL treatment are statistically significant increased (P <0.001) versus baseline (P = 0.007) versus placebo. Conclusions: These in vivo data demonstrate that RAL could improve osteoporosis, also through an increase of OPG production by osteoblasts.

AB - Objectives: Osteoprotegerin (OPG) is a protein expressed by osteoblasts that, linking the receptor activator of nuclear factor κB (RANK) ligand (RANKL), produced by osteoblasts, blocks the process of osteoclastic differentiation and modulates osteoclastic apoptosis. Raloxifene (RAL) stimulates the production of OPG from osteoblasts, as demonstrated in vitro, carring out their antiresorption activity, at least in part, as means of the OPG/RANK/RANKL system. The aim of this study was to evaluate in vivo if the RAL treatment of postmenopausal women was associated to changes in serum OPG; moreover, to evaluate the serum changes of bone turnover modulators interleukin-6 (IL-6) and C-telopeptides of type-1 collagen (CrossLaps). Methods: A prospective, randomized, placebo-controlled study was designed. A group of consecutive healthy postmenopausal women (n = 40) referred to II Menopause Centre of the Department of Gynaecology of Second University of Naples for climacteric syndrome was enrolled and divided in two groups: (n = 20) postmenopausal women received for 6 months oral raloxifene (60 mg/day) versus (n = 20) postmenopausal women received placebo tablets. Results: Serum OPG levels in postmenopausal women after RAL treatment are statistically significant increased (P <0.001) versus baseline (P = 0.007) versus placebo. Conclusions: These in vivo data demonstrate that RAL could improve osteoporosis, also through an increase of OPG production by osteoblasts.

KW - Menopause

KW - Osteoporosis

KW - Osteoprotegerin

KW - Raloxifene

UR - http://www.scopus.com/inward/record.url?scp=33845402400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845402400&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2006.05.007

DO - 10.1016/j.maturitas.2006.05.007

M3 - Article

C2 - 16787719

AN - SCOPUS:33845402400

VL - 56

SP - 38

EP - 44

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 1

ER -